These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28683725)

  • 1. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
    Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
    Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
    Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
    Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.
    Lopez MF; Mikulskis A; Kuzdzal S; Golenko E; Petricoin EF; Liotta LA; Patton WF; Whiteley GR; Rosenblatt K; Gurnani P; Nandi A; Neill S; Cullen S; O'Gorman M; Sarracino D; Lynch C; Johnson A; Mckenzie W; Fishman D
    Clin Chem; 2007 Jun; 53(6):1067-74. PubMed ID: 17463175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
    Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
    Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X
    Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
    Shevchenko VE; Arnotskaya NE; Zaridze DG
    Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers.
    Wang H; Kachman MT; Schwartz DR; Cho KR; Lubman DM
    Proteomics; 2004 Aug; 4(8):2476-95. PubMed ID: 15274142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
    Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
    Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
    Nanni P; Parisi D; Roda G; Casale M; Belluzzi A; Roda E; Mayer L; Roda A
    Rapid Commun Mass Spectrom; 2007; 21(24):4142-8. PubMed ID: 18022963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.
    Gagné JP; Gagné P; Hunter JM; Bonicalzi ME; Lemay JF; Kelly I; Le Page C; Provencher D; Mes-Masson AM; Droit A; Bourgais D; Poirier GG
    Mol Cell Biochem; 2005 Jul; 275(1-2):25-55. PubMed ID: 16335783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Epithelial Ovarian Cancer using C8Magnetic Bead Separation and MALDI-TOF Plasma Proteome Profiling in Egyptian Females.
    Rizk MM; Sharaki OA; Meleis ME; Younan DN; Elkial AA; Moez P
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3603-3609. PubMed ID: 31870100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
    Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
    J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry.
    Kim NA; Jin JH; Kim KH; Lim DG; Cheong H; Kim YH; Ju W; Kim SC; Jeong SH
    Arch Pharm Res; 2016 May; 39(5):668-76. PubMed ID: 27002828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.
    Li K; Pei Y; Wu Y; Guo Y; Cui W
    J Ovarian Res; 2020 Jan; 13(1):6. PubMed ID: 31924227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
    Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
    Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC/Q-TOF MS.
    Yang W; Mu T; Jiang J; Sun Q; Hou X; Sun Y; Zhong L; Wang C; Sun C
    Cell Physiol Biochem; 2018; 51(3):1134-1148. PubMed ID: 30476914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
    Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I
    Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.